Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation.

Fife KL, Liu Y, Schmelzer KR, Tsai HJ, Kim IH, Morisseau C, Hammock BD, Kroetz DL.

J Pharmacol Exp Ther. 2008 Dec;327(3):707-15. doi: 10.1124/jpet.108.142398. Epub 2008 Sep 24.

2.

Soluble epoxide hydrolase: a new target for cardioprotection.

Gross GJ, Nithipatikom K.

Curr Opin Investig Drugs. 2009 Mar;10(3):253-8. Review.

3.

Soluble epoxide hydrolase: gene structure, expression and deletion.

Harris TR, Hammock BD.

Gene. 2013 Sep 10;526(2):61-74. doi: 10.1016/j.gene.2013.05.008. Epub 2013 May 20. Review.

4.

Epoxyeicosatrienoic acid pathway in human health and diseases.

Bellien J, Joannides R.

J Cardiovasc Pharmacol. 2013 Mar;61(3):188-96. doi: 10.1097/FJC.0b013e318273b007. Review.

PMID:
23011468
5.

Soluble epoxide hydrolase inhibitors and heart failure.

Qiu H, Li N, Liu JY, Harris TR, Hammock BD, Chiamvimonvat N.

Cardiovasc Ther. 2011 Apr;29(2):99-111. doi: 10.1111/j.1755-5922.2010.00150.x. Review.

6.

Arachidonic acid cytochrome P450 epoxygenase pathway.

Spector AA.

J Lipid Res. 2009 Apr;50 Suppl:S52-6. doi: 10.1194/jlr.R800038-JLR200. Epub 2008 Oct 23. Review.

7.

Targeting soluble epoxide hydrolase for inflammation and pain - an overview of pharmacology and the inhibitors.

Pillarisetti S, Khanna I.

Inflamm Allergy Drug Targets. 2012 Apr;11(2):143-58. Review.

PMID:
22280237
8.

Soluble epoxide hydrolase: a novel target for the treatment of hypertension.

Fang X.

Recent Pat Cardiovasc Drug Discov. 2006 Jan;1(1):67-72. Review.

PMID:
18221075
9.

Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.

Elmarakby AA.

Am J Physiol Regul Integr Comp Physiol. 2012 Feb 1;302(3):R321-30. doi: 10.1152/ajpregu.00606.2011. Epub 2011 Nov 23. Review.

10.

Soluble epoxide hydrolase: a promising therapeutic target for cardiovascular diseases.

Ni GH, Chen JF, Chen XP, Yang TL.

Pharmazie. 2011 Mar;66(3):153-7. Review.

PMID:
21553642
11.

Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.

Revermann M.

Curr Opin Pharmacol. 2010 Apr;10(2):173-8. doi: 10.1016/j.coph.2009.12.002. Epub 2010 Jan 14. Review.

PMID:
20079692
12.

Soluble epoxide hydrolase: A potential target for metabolic diseases.

He J, Wang C, Zhu Y, Ai D.

J Diabetes. 2016 May;8(3):305-13. doi: 10.1111/1753-0407.12358. Epub 2016 Jan 9. Review.

PMID:
26621325
13.

Targeting epoxides for organ damage in hypertension.

Imig JD.

J Cardiovasc Pharmacol. 2010 Oct;56(4):329-35. doi: 10.1097/FJC.0b013e3181e96e0c. Review.

14.

Inside epoxyeicosatrienoic acids and cardiovascular disease.

Tacconelli S, Patrignani P.

Front Pharmacol. 2014 Nov 10;5:239. doi: 10.3389/fphar.2014.00239. eCollection 2014 Nov 10. Review.

15.

Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception.

Wagner K, Inceoglu B, Hammock BD.

Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):76-83. doi: 10.1016/j.prostaglandins.2011.08.001. Epub 2011 Aug 10. Review.

16.

Red blood cells (RBCs), epoxyeicosatrienoic acids (EETs) and adenosine triphosphate (ATP).

Jiang H, Anderson GD, McGiff JC.

Pharmacol Rep. 2010 May-Jun;62(3):468-74. Review.

17.

The red blood cell participates in regulation of the circulation by producing and releasing epoxyeicosatrienoic acids.

Jiang H, Anderson GD, McGiff JC.

Prostaglandins Other Lipid Mediat. 2012 Aug;98(3-4):91-3. doi: 10.1016/j.prostaglandins.2011.11.008. Epub 2011 Dec 8. Review.

18.

Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders.

Inoue K, Takano H.

Expert Opin Investig Drugs. 2010 Apr;19(4):513-20. doi: 10.1517/13543781003649533. Review.

PMID:
20367192

Supplemental Content

Support Center